Risks of cutaneous immune‐related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Hyejun Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Research Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
Previous research has not investigated the persistent cutaneous immune‐related adverse events (cirAEs) related to long COVID to investigate the long‐term sequelae. This multinational study, using a propensity‐matched overlap weighting method, utilizes large national claims‐based cohorts, using ICD‐10 code diagnosis, focusing on patients aged ≥20 years from three countries: South Korean, Japanese, and the British cohorts. To estimate the risk of cirAEs in long COVID, the persistence or emergence of cirAEs occurring 4 weeks after the initial SARS‐CoV‐2 infection, we employed a Cox proportional hazard regression model. The Korean cohort ( n = 5,937,373; mean age 49.2 years [SD: 13.2]), the Japanese cohort ( n = 4,307,587; 42.5 years [13.6]), and the UK cohort ( n = 395,435; 71.0 years [8.07]) were presented. An increased risk of cirAEs in long COVID was observed (HR, 1.10; 95% CI, 1.06–1.14) in Korean cohort, while a similar association was observed in Japanese and UK cohorts. The long‐term risk of cirAEs in long COVID was higher in more severe COVID‐19 cases (1.31; 1.22–1.39). Unlike the increased risk of cirAEs in long COVID, COVID‐19 vaccination attenuated the risk, especially with two or more doses (1.03; 0.95–1.11) or heterologous regimens (0.98; 0.76–1.27). The time attenuation effect indicated a sustained risk for up to 6 months postinfection (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Applied Information Engineering, Yonsei University, Seoul, South Korea.
- Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
- Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
- Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.
- Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran.
ORCID-Profile: Masoud Rahmati, Dong Keon Yon
Förderung
- National Research Foundation
Zitieren
APA
Kim, H., Kyung, S., Park, J., Lee, H., Lee, M., Smith, L., Rahmati, M., Shin, J. Y., Kang, J., Jacob, L., Papadopoulos, N. G., Rhee, S. Y., Lee, J., Kim, H. J., Lee, H., & Yon, D. K. (2024). Risks of cutaneous immune‐related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK. Journal of Medical Virology. https://doi.org/10.1002/jmv.29740
Vancouver
Kim H, Kyung S, Park J, Lee H, Lee M, Smith L, et al. Risks of cutaneous immune‐related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK. Journal of Medical Virology. 2024. doi:10.1002/jmv.29740
BibTeX
@article{Kim2024,
author = {Kim, Hyejun and Kyung, Seoyeon and Park, Jaeyu and Lee, Hojae and Lee, Myeongcheol and Smith, Lee and Rahmati, Masoud and Shin, Ju-Young and Kang, Jiseung and Jacob, Louis and Papadopoulos, Nikolaos G and Rhee, Sang Youl and Lee, Jinseok and Kim, Hyeon Jin and Lee, Hayeon and Yon, Dong Keon},
title = {Risks of cutaneous immune‐related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29740}
}
EUVIMED